Global Influenza Diagnostics Market Overview

Global Influenza Diagnostics Market was valued at USD 0.86 billion in 2021 and is expected to reach USD 1.3 billion by the year 2028, at a CAGR of 7.4%.

Influenza, popularly known as flu, is a respiratory disorder caused by a virus. The transmission of the flu virus usually occurs from person to person through coughing or sneezing. In addition, one can also get the flu by touching a contaminated surface that has the flu virus on it, and then touching the nose or eyes. The flu is most common during certain times of the year, known as seasonal flu. Moreover, In the United States, flu season can begin as early as October and end as late as May. During each flu season, millions of Americans get infected by the flu virus. The common flu symptoms faced by individuals are muscle aches, fever, and other uncomfortable symptoms, but will recover within a week. For others, influenza can cause very serious illness, and even cause death in certain cases. Furthermore, influenza diagnostic tests aid the healthcare provider in early detection of the flu and treating the disease at the earliest thus promoting the expansion of the Influenza Diagnostic Market in the forecast period. Furthermore, the appropriate treatment of patients with respiratory disorders depends on accurate and timely diagnosis. Additionally, early diagnosis of influenza can decrease the inappropriate usage of antibiotics and provide the option of using antiviral therapy to treat flu thus, encouraging the growth of the Influenza Diagnostic Market during the forecast period. 

Market Dynamics and Factors of Influenza Diagnostics Market:

Drivers:

The increase in the number of influenza outbreaks in recent years has stimulated the demand for accurate detection of the influenza virus. Moreover, influenza diagnostic tests also help in confirming or excluding the presence of the virus in symptomatic persons thus, driving the expansion of the Influenza Diagnostic Market during the forecast period. According to a WHO report in 2019, influenza caused severe sickness or death mainly in patients at high risks such as pregnant women, children, and the geriatric population. Furthermore, the degree of illness ranges from mild to severe and even death in certain cases. More than 290000 to 650000 influenza-associated deaths occur every year, thus to diagnose the disease and to provide proper treatment to the infected individual's diagnostics tests play an important role, therefore, stimulating the development of the Influenza Diagnostic Market during the forecast period. The increasing awareness among the population about the importance of early detection of disease is the major element encouraging the positive progress of the Influenza Diagnostic Market in the forecast period.

Restraints:

The main factor hampering the growth of the Influenza Diagnostic Market is the method of collecting a swab from a nasal or oral source. Moreover, the sensitivity and specificity of different methods also impact the results of the influenza diagnostic tests. The variations found in influenza viruses affect the accuracy of the tests and can result in false-negative and false-positive results. Furthermore, the traditional methods are less sensitive as compared to advance molecular tests. A false-positive test may lead to an incorrect diagnosis of the disease, hence unnecessary testing, or unnecessary treatment. Unnecessary influenza diagnostic tests generate unnecessary labor, reagent, and equipment costs, and lead to high health care expenditures thus, restricting the expansion of the Influenza Diagnostic Market during the forecast period.

Opportunities:

The rise in the number of cases of individuals suffering from influenza and the growing need for early detection of the influenza virus are providing vital opportunities for market players to develop diagnostics tests that are rapid and can produce accurate results. Moreover, governments across the globe are investing in research and development activities of influenza diagnostics tests to reduce the economic burden caused by the widespread influenza disease. Furthermore, the technological advancements in genomics and proteomics attributed to the Human Genome Project have resulted in the development of novel diagnosing techniques that can be utilized to manage influenza infections. These new technologies have enabled researchers to discover new influenza viruses present in the environment. Thus, to provide a rapid and accurate diagnosis of infectious diseases these new technologies such as RT-PCR have proved a boon, therefore, serve as an opportunity for the market players.

Market Segmentation

Based on test type, the Influenza Diagnostic Market is segmented into traditional and molecular tests. The Rapid Influenza Detection Tests (RIDTs) a type of traditional test segment is forecasted to dominate the Influenza Diagnostic Market. The ability to detect influenza viruses within 15 minutes with low to moderate sensitivity and high specificity is the important factor driving the growth of this segment. Moreover, an analyzer reader device can be utilized to improve the sensitivity of RIDTs and standardize its results. Many RIDTs are the Clinical Laboratory Improvement Amendment (CLIA) waived, that's means they are very simple to perform and do not need scientifically qualified personnel. The RT-PCR test from the molecular test segment is expected to have the highest growth rate in the forecast period. RT-PCR test can detect current infection of influenza, enabling the healthcare provider to determine who is currently infected and who is not. Moreover, it is a highly sensitive test that can detect the presence of influenza virus in low concentration as well, therefore, stimulating the rapid development of the RT PCR test in the forecast period.

Based on end-users, the diagnostic laboratories segment is expected to lead the Influenza Diagnostic Market throughout the forecast. The rising number of diagnostic laboratories and the increase in outsourcing of diagnostic testing services to large commercial diagnostic laboratories by hospitals is the vital factor promoting the development of this segment. Moreover, the well-deployed collection centers of large commercial diagnostic laboratories and the discounts offered by diagnostic laboratories on expensive tests are further propelling the expansion of this segment.

Players Covered in Influenza Diagnostics market are :

• Danaher Corporation (US)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific Inc. (US)
• F. Hoffmann-LA Roche AG (Switzerland)
• Abbott Laboratories Inc. (Us)
• Hologic Inc. (US)
• bioMérieux SA (France)
• Quidel Corporation (US)
• Becton
• Dickinson and Company (US)
• Meridian Bioscience (US)
• GenMark Diagnostics Inc. (US)
• Luminex Corporation (US)
• Tecan Trading AG (Switzerland)
• DiaSorin SA (Italy)
• altona Diagnostics GmbH (Germany)
• SEKISUI Diagnostics (US)
• SA Scientific Ltd. (US)
• Coris BioConcept SPRL (Belgium)
• ELITech Group (France)
• Mast Group Ltd. (UK)
• Genome Diagnostics Pvt. Ltd. (India)
• Germaine Laboratories Inc. (US)
• Response Biomedical Corp. (Canada)
• Tauns LaboratoriesInc. (Japan)
• 3B BlackBio Biotech India Ltd. (India) and Others major players.

Regional Analysis of Influenza Diagnostics Market:

The North American region is forecasted to have the highest share of the Influenza Diagnostic Market in the period of forecast. The presence of top leading companies involved in the manufacturing of Influenza Diagnostic products and the huge spending of governments on the development of novel fast diagnosing techniques to detect influenzas is the main factor supporting the expansion of the Influenza Diagnostic Market in this region. The high prevalence of seasonal flu and the rise in the adoption of technologically advanced diagnostic products is further boosting the growth of the Influenza Diagnostic Market in the forecast period.
The Europe region followed by North America is anticipated to have the second-highest share of the Influenza Diagnostic Market throughout the forecast. The presence of top research and academic institutes, and the increase in the research and development activities supported by governments funding are the vital factors fueling the Influenza Diagnostic Market growth in this region. Moreover, the rising incidences of bird flu, influenzas, and increasing demand for early detection of flu diseases are spurring the expansion of the Influenza Diagnostic Market in this region.  
The Asia-Pacific region is expected to grow at the highest growth rate during the forecast period. A large number of an aging population and their high susceptibility to various diseases including influenza is the prominent factor driving the growth of the Influenza Diagnostic Market in this region. Moreover, the initiatives taken by governments in this region to enable faster diagnosis have facilitated easy access to over-the-counter tests that are user-friendly and assist in timely diagnosis. The wide use of rapid influenza diagnostics tests is propelling the development of the Influenza Diagnostic Market in this region.

Key Industry Developments in Influenza Diagnostics Market:

• In March 2021, BD (Becton, Dickinson, and Company), a top global provider of influenza diagnostic products, declared that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for a novel, rapid antigen test that can detect influenza A, influenza B and SARS-CoV-2 in a single test. The BD Veritor System developed for Rapid Detection of SARS-CoV-2 and Flu A+B assay requires only 15 minutes to run on the BD Veritor Plus System and differentiates between SARS-CoV-2, influenza A and influenza B, by giving conclusive positive or negative individual digital display readouts for all the three viruses.
• In July 2021, DiaSorin SpA, a global diagnostic company, declared that it has completed the takeover of Luminex Corporation. Through the acquisition, DiaSorin will be able to access the multiplexing technology of Luminex and a portfolio that will consolidate the DiaSorin existing offering, while promoting the expansion of DiaSorin in the United States. In addition, this deal will render access to Luminex's services throughout the Life Science industry, and will also provide access to academic and scientific research.
• In September 2021, Roche declared the commercialization of three molecular PCR diagnostic tests which can detect and differentiate common respiratory pathogens simultaneously, of which one test is the detection and identification of influenza A, influenza B, and respiratory syncytial virus (RSV). All three tests can be performed together or individually from a single nasopharyngeal swab specimen.

COVID-19 Impact on Influenza Diagnostics Market:

The outbreak of COVID-19 in 2020 has significantly affected the functioning of several industries. The restrictions imposed by the governments worldwide, on transportation and gathering of workers, resulted in a shortage of raw material required for various industries and a decrease in the production of goods respectively. Moreover, the disruptions in the supply chain created a huge gap in the demand and supply of Influenza Diagnostic products. In addition, the limited functioning in Influenza Diagnostic industries resulted in decreased supply of Influenza Diagnostic products to end-users. The outbreak of the COVID-19 pandemic has altered the delivery of medical care across the world. Furthermore, the similarities between both seasonal flu (influenza A and B) and COVID-19 and the contagious nature of both viruses, show similar symptoms of respiratory illness. This propelled the demand for the development of novel techniques to detect and differentiate the viruses from one another, thus propelling the growth of the Influenza Diagnostic Market in the pandemic period. To promote the research activities several philanthropists and governments provided funds to research institutes.  The viral nature of the COVID-19 strain is the main factor that propelled the Influenza Diagnostic Market development.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By End Users

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Influenza Diagnostics Market by Type
 5.1 Influenza Diagnostics Market Overview Snapshot and Growth Engine
 5.2 Influenza Diagnostics Market Overview
 5.3 Traditional {Rapid Influenza Detection Tests
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Traditional {Rapid Influenza Detection Tests: Grographic Segmentation
 5.4 Viral Culture
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Viral Culture: Grographic Segmentation
 5.5 Immunoassay Kits
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Immunoassay Kits: Grographic Segmentation
 5.6 Immunofluorescence Assays
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Immunofluorescence Assays: Grographic Segmentation
 5.7 Serological Testing}
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Serological Testing}: Grographic Segmentation
 5.8 Molecular {Rapid Molecular Assays
  5.8.1 Introduction and Market Overview
  5.8.2 Historic and Forecasted Market Size (2016-2028F)
  5.8.3 Key Market Trends, Growth Factors and Opportunities
  5.8.4 Molecular {Rapid Molecular Assays: Grographic Segmentation
 5.9 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  5.9.1 Introduction and Market Overview
  5.9.2 Historic and Forecasted Market Size (2016-2028F)
  5.9.3 Key Market Trends, Growth Factors and Opportunities
  5.9.4 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}: Grographic Segmentation
 5.10 Nucleic Acid Amplification
  5.10.1 Introduction and Market Overview
  5.10.2 Historic and Forecasted Market Size (2016-2028F)
  5.10.3 Key Market Trends, Growth Factors and Opportunities
  5.10.4 Nucleic Acid Amplification: Grographic Segmentation

Chapter 6: Influenza Diagnostics Market by End Users
 6.1 Influenza Diagnostics Market Overview Snapshot and Growth Engine
 6.2 Influenza Diagnostics Market Overview
 6.3 Clinical Laboratories
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2016-2028F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Clinical Laboratories: Grographic Segmentation
 6.4 Hospitals
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2016-2028F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Hospitals: Grographic Segmentation
 6.5 Research & Academic Institutes
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2016-2028F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Research & Academic Institutes: Grographic Segmentation
 6.6 Diagnostic Laboratories
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2016-2028F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Diagnostic Laboratories: Grographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Influenza Diagnostics Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Ansoff Matrix
  7.1.5 Influenza Diagnostics Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Influenza Diagnostics Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 DANAHER CORPORATION
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 SIEMENS HEALTHINEERS
 7.4 THERMO FISHER SCIENTIFIC INC.
 7.5 F. HOFFMANN-LA ROCHE AG
 7.6 ABBOTT LABORATORIES INC.
 7.7 HOLOGIC INC.
 7.8 BIOMÉRIEUX SA
 7.9 QUIDEL CORPORATION
 7.10 BECTON
 7.11 DICKINSON AND COMPANY
 7.12 MERIDIAN BIOSCIENCE
 7.13 GENMARK DIAGNOSTICS INC.
 7.14 LUMINEX CORPORATION
 7.15 TECAN TRADING AG
 7.16 DIASORIN SA
 7.17 ALTONA DIAGNOSTICS GMBH
 7.18 SEKISUI DIAGNOSTICS
 7.19 SA SCIENTIFIC LTD.
 7.20 CORIS BIOCONCEPT SPRL
 7.21 ELITECH GROUP
 7.22 MAST GROUP LTD.
 7.23 GENOME DIAGNOSTICS PVT. LTD.
 7.24 GERMAINE LABORATORIES INC.
 7.25 RESPONSE BIOMEDICAL CORP.
 7.26 TAUNS LABORATORIESINC.
 7.27 3B BLACKBIO BIOTECH INDIA LTD.
 7.28 OTHER MAJOR PLAYERS

Chapter 8: Global Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 Traditional {Rapid Influenza Detection Tests
  8.2.2 Viral Culture
  8.2.3 Immunoassay Kits
  8.2.4 Immunofluorescence Assays
  8.2.5 Serological Testing}
  8.2.6 Molecular {Rapid Molecular Assays
  8.2.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  8.2.8 Nucleic Acid Amplification
 8.3 Historic and Forecasted Market Size By End Users
  8.3.1 Clinical Laboratories
  8.3.2 Hospitals
  8.3.3 Research & Academic Institutes
  8.3.4 Diagnostic Laboratories

Chapter 9: North America Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Traditional {Rapid Influenza Detection Tests
  9.4.2 Viral Culture
  9.4.3 Immunoassay Kits
  9.4.4 Immunofluorescence Assays
  9.4.5 Serological Testing}
  9.4.6 Molecular {Rapid Molecular Assays
  9.4.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  9.4.8 Nucleic Acid Amplification
 9.5 Historic and Forecasted Market Size By End Users
  9.5.1 Clinical Laboratories
  9.5.2 Hospitals
  9.5.3 Research & Academic Institutes
  9.5.4 Diagnostic Laboratories
 9.6 Historic and Forecast Market Size by Country
  9.6.1 U.S.
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Europe Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Traditional {Rapid Influenza Detection Tests
  10.4.2 Viral Culture
  10.4.3 Immunoassay Kits
  10.4.4 Immunofluorescence Assays
  10.4.5 Serological Testing}
  10.4.6 Molecular {Rapid Molecular Assays
  10.4.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  10.4.8 Nucleic Acid Amplification
 10.5 Historic and Forecasted Market Size By End Users
  10.5.1 Clinical Laboratories
  10.5.2 Hospitals
  10.5.3 Research & Academic Institutes
  10.5.4 Diagnostic Laboratories
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Germany
  10.6.2 U.K.
  10.6.3 France
  10.6.4 Italy
  10.6.5 Russia
  10.6.6 Spain
  10.6.7 Rest of Europe

Chapter 11: Asia-Pacific Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Traditional {Rapid Influenza Detection Tests
  11.4.2 Viral Culture
  11.4.3 Immunoassay Kits
  11.4.4 Immunofluorescence Assays
  11.4.5 Serological Testing}
  11.4.6 Molecular {Rapid Molecular Assays
  11.4.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  11.4.8 Nucleic Acid Amplification
 11.5 Historic and Forecasted Market Size By End Users
  11.5.1 Clinical Laboratories
  11.5.2 Hospitals
  11.5.3 Research & Academic Institutes
  11.5.4 Diagnostic Laboratories
 11.6 Historic and Forecast Market Size by Country
  11.6.1 China
  11.6.2 India
  11.6.3 Japan
  11.6.4 Singapore
  11.6.5 Australia
  11.6.6 New Zealand
  11.6.7 Rest of APAC

Chapter 12: Middle East & Africa Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Traditional {Rapid Influenza Detection Tests
  12.4.2 Viral Culture
  12.4.3 Immunoassay Kits
  12.4.4 Immunofluorescence Assays
  12.4.5 Serological Testing}
  12.4.6 Molecular {Rapid Molecular Assays
  12.4.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  12.4.8 Nucleic Acid Amplification
 12.5 Historic and Forecasted Market Size By End Users
  12.5.1 Clinical Laboratories
  12.5.2 Hospitals
  12.5.3 Research & Academic Institutes
  12.5.4 Diagnostic Laboratories
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Turkey
  12.6.2 Saudi Arabia
  12.6.3 Iran
  12.6.4 UAE
  12.6.5 Africa
  12.6.6 Rest of MEA

Chapter 13: South America Influenza Diagnostics Market Analysis, Insights and Forecast, 2016-2028
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Traditional {Rapid Influenza Detection Tests
  13.4.2 Viral Culture
  13.4.3 Immunoassay Kits
  13.4.4 Immunofluorescence Assays
  13.4.5 Serological Testing}
  13.4.6 Molecular {Rapid Molecular Assays
  13.4.7 Reverse Transcription-Polymerase Chain Reaction {Rt-Pcr}
  13.4.8 Nucleic Acid Amplification
 13.5 Historic and Forecasted Market Size By End Users
  13.5.1 Clinical Laboratories
  13.5.2 Hospitals
  13.5.3 Research & Academic Institutes
  13.5.4 Diagnostic Laboratories
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Brazil
  13.6.2 Argentina
  13.6.3 Rest of SA

Chapter 14 Investment Analysis

Chapter 15 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. INFLUENZA DIAGNOSTICS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. INFLUENZA DIAGNOSTICS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. INFLUENZA DIAGNOSTICS MARKET COMPETITIVE RIVALRY
TABLE 005. INFLUENZA DIAGNOSTICS MARKET THREAT OF NEW ENTRANTS
TABLE 006. INFLUENZA DIAGNOSTICS MARKET THREAT OF SUBSTITUTES
TABLE 007. INFLUENZA DIAGNOSTICS MARKET BY TYPE
TABLE 008. TRADITIONAL {RAPID INFLUENZA DETECTION TESTS MARKET OVERVIEW (2016-2028)
TABLE 009. VIRAL CULTURE MARKET OVERVIEW (2016-2028)
TABLE 010. IMMUNOASSAY KITS MARKET OVERVIEW (2016-2028)
TABLE 011. IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW (2016-2028)
TABLE 012. SEROLOGICAL TESTING} MARKET OVERVIEW (2016-2028)
TABLE 013. MOLECULAR {RAPID MOLECULAR ASSAYS MARKET OVERVIEW (2016-2028)
TABLE 014. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION {RT-PCR} MARKET OVERVIEW (2016-2028)
TABLE 015. NUCLEIC ACID AMPLIFICATION MARKET OVERVIEW (2016-2028)
TABLE 016. INFLUENZA DIAGNOSTICS MARKET BY END USERS
TABLE 017. CLINICAL LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 018. HOSPITALS MARKET OVERVIEW (2016-2028)
TABLE 019. RESEARCH & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
TABLE 020. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
TABLE 021. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 022. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 023. N INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 024. EUROPE INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 025. EUROPE INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 026. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 027. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 028. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 029. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 030. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 031. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 032. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 033. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY TYPE (2016-2028)
TABLE 034. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET, BY END USERS (2016-2028)
TABLE 035. INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY (2016-2028)
TABLE 036. DANAHER CORPORATION: SNAPSHOT
TABLE 037. DANAHER CORPORATION: BUSINESS PERFORMANCE
TABLE 038. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 039. DANAHER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. SIEMENS HEALTHINEERS: SNAPSHOT
TABLE 040. SIEMENS HEALTHINEERS: BUSINESS PERFORMANCE
TABLE 041. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO
TABLE 042. SIEMENS HEALTHINEERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. THERMO FISHER SCIENTIFIC INC.: SNAPSHOT
TABLE 043. THERMO FISHER SCIENTIFIC INC.: BUSINESS PERFORMANCE
TABLE 044. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
TABLE 045. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. F. HOFFMANN-LA ROCHE AG: SNAPSHOT
TABLE 046. F. HOFFMANN-LA ROCHE AG: BUSINESS PERFORMANCE
TABLE 047. F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 048. F. HOFFMANN-LA ROCHE AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ABBOTT LABORATORIES INC.: SNAPSHOT
TABLE 049. ABBOTT LABORATORIES INC.: BUSINESS PERFORMANCE
TABLE 050. ABBOTT LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 051. ABBOTT LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. HOLOGIC INC.: SNAPSHOT
TABLE 052. HOLOGIC INC.: BUSINESS PERFORMANCE
TABLE 053. HOLOGIC INC.: PRODUCT PORTFOLIO
TABLE 054. HOLOGIC INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. BIOMÉRIEUX SA: SNAPSHOT
TABLE 055. BIOMÉRIEUX SA: BUSINESS PERFORMANCE
TABLE 056. BIOMÉRIEUX SA: PRODUCT PORTFOLIO
TABLE 057. BIOMÉRIEUX SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. QUIDEL CORPORATION: SNAPSHOT
TABLE 058. QUIDEL CORPORATION: BUSINESS PERFORMANCE
TABLE 059. QUIDEL CORPORATION: PRODUCT PORTFOLIO
TABLE 060. QUIDEL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. BECTON: SNAPSHOT
TABLE 061. BECTON: BUSINESS PERFORMANCE
TABLE 062. BECTON: PRODUCT PORTFOLIO
TABLE 063. BECTON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. DICKINSON AND COMPANY: SNAPSHOT
TABLE 064. DICKINSON AND COMPANY: BUSINESS PERFORMANCE
TABLE 065. DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 066. DICKINSON AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. MERIDIAN BIOSCIENCE: SNAPSHOT
TABLE 067. MERIDIAN BIOSCIENCE: BUSINESS PERFORMANCE
TABLE 068. MERIDIAN BIOSCIENCE: PRODUCT PORTFOLIO
TABLE 069. MERIDIAN BIOSCIENCE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. GENMARK DIAGNOSTICS INC.: SNAPSHOT
TABLE 070. GENMARK DIAGNOSTICS INC.: BUSINESS PERFORMANCE
TABLE 071. GENMARK DIAGNOSTICS INC.: PRODUCT PORTFOLIO
TABLE 072. GENMARK DIAGNOSTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. LUMINEX CORPORATION: SNAPSHOT
TABLE 073. LUMINEX CORPORATION: BUSINESS PERFORMANCE
TABLE 074. LUMINEX CORPORATION: PRODUCT PORTFOLIO
TABLE 075. LUMINEX CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 075. TECAN TRADING AG: SNAPSHOT
TABLE 076. TECAN TRADING AG: BUSINESS PERFORMANCE
TABLE 077. TECAN TRADING AG: PRODUCT PORTFOLIO
TABLE 078. TECAN TRADING AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 078. DIASORIN SA: SNAPSHOT
TABLE 079. DIASORIN SA: BUSINESS PERFORMANCE
TABLE 080. DIASORIN SA: PRODUCT PORTFOLIO
TABLE 081. DIASORIN SA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 081. ALTONA DIAGNOSTICS GMBH: SNAPSHOT
TABLE 082. ALTONA DIAGNOSTICS GMBH: BUSINESS PERFORMANCE
TABLE 083. ALTONA DIAGNOSTICS GMBH: PRODUCT PORTFOLIO
TABLE 084. ALTONA DIAGNOSTICS GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 084. SEKISUI DIAGNOSTICS: SNAPSHOT
TABLE 085. SEKISUI DIAGNOSTICS: BUSINESS PERFORMANCE
TABLE 086. SEKISUI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 087. SEKISUI DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 087. SA SCIENTIFIC LTD.: SNAPSHOT
TABLE 088. SA SCIENTIFIC LTD.: BUSINESS PERFORMANCE
TABLE 089. SA SCIENTIFIC LTD.: PRODUCT PORTFOLIO
TABLE 090. SA SCIENTIFIC LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 090. CORIS BIOCONCEPT SPRL: SNAPSHOT
TABLE 091. CORIS BIOCONCEPT SPRL: BUSINESS PERFORMANCE
TABLE 092. CORIS BIOCONCEPT SPRL: PRODUCT PORTFOLIO
TABLE 093. CORIS BIOCONCEPT SPRL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 093. ELITECH GROUP: SNAPSHOT
TABLE 094. ELITECH GROUP: BUSINESS PERFORMANCE
TABLE 095. ELITECH GROUP: PRODUCT PORTFOLIO
TABLE 096. ELITECH GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 096. MAST GROUP LTD.: SNAPSHOT
TABLE 097. MAST GROUP LTD.: BUSINESS PERFORMANCE
TABLE 098. MAST GROUP LTD.: PRODUCT PORTFOLIO
TABLE 099. MAST GROUP LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 099. GENOME DIAGNOSTICS PVT. LTD.: SNAPSHOT
TABLE 100. GENOME DIAGNOSTICS PVT. LTD.: BUSINESS PERFORMANCE
TABLE 101. GENOME DIAGNOSTICS PVT. LTD.: PRODUCT PORTFOLIO
TABLE 102. GENOME DIAGNOSTICS PVT. LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. GERMAINE LABORATORIES INC.: SNAPSHOT
TABLE 103. GERMAINE LABORATORIES INC.: BUSINESS PERFORMANCE
TABLE 104. GERMAINE LABORATORIES INC.: PRODUCT PORTFOLIO
TABLE 105. GERMAINE LABORATORIES INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. RESPONSE BIOMEDICAL CORP.: SNAPSHOT
TABLE 106. RESPONSE BIOMEDICAL CORP.: BUSINESS PERFORMANCE
TABLE 107. RESPONSE BIOMEDICAL CORP.: PRODUCT PORTFOLIO
TABLE 108. RESPONSE BIOMEDICAL CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 108. TAUNS LABORATORIESINC.: SNAPSHOT
TABLE 109. TAUNS LABORATORIESINC.: BUSINESS PERFORMANCE
TABLE 110. TAUNS LABORATORIESINC.: PRODUCT PORTFOLIO
TABLE 111. TAUNS LABORATORIESINC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 111. 3B BLACKBIO BIOTECH INDIA LTD.: SNAPSHOT
TABLE 112. 3B BLACKBIO BIOTECH INDIA LTD.: BUSINESS PERFORMANCE
TABLE 113. 3B BLACKBIO BIOTECH INDIA LTD.: PRODUCT PORTFOLIO
TABLE 114. 3B BLACKBIO BIOTECH INDIA LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 114. OTHER MAJOR PLAYERS: SNAPSHOT
TABLE 115. OTHER MAJOR PLAYERS: BUSINESS PERFORMANCE
TABLE 116. OTHER MAJOR PLAYERS: PRODUCT PORTFOLIO
TABLE 117. OTHER MAJOR PLAYERS: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY TYPE
FIGURE 012. TRADITIONAL {RAPID INFLUENZA DETECTION TESTS MARKET OVERVIEW (2016-2028)
FIGURE 013. VIRAL CULTURE MARKET OVERVIEW (2016-2028)
FIGURE 014. IMMUNOASSAY KITS MARKET OVERVIEW (2016-2028)
FIGURE 015. IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 016. SEROLOGICAL TESTING} MARKET OVERVIEW (2016-2028)
FIGURE 017. MOLECULAR {RAPID MOLECULAR ASSAYS MARKET OVERVIEW (2016-2028)
FIGURE 018. REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION {RT-PCR} MARKET OVERVIEW (2016-2028)
FIGURE 019. NUCLEIC ACID AMPLIFICATION MARKET OVERVIEW (2016-2028)
FIGURE 020. INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY END USERS
FIGURE 021. CLINICAL LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 022. HOSPITALS MARKET OVERVIEW (2016-2028)
FIGURE 023. RESEARCH & ACADEMIC INSTITUTES MARKET OVERVIEW (2016-2028)
FIGURE 024. DIAGNOSTIC LABORATORIES MARKET OVERVIEW (2016-2028)
FIGURE 025. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 026. EUROPE INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 027. ASIA PACIFIC INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 028. MIDDLE EAST & AFRICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 029. SOUTH AMERICA INFLUENZA DIAGNOSTICS MARKET OVERVIEW BY COUNTRY (2016-2028)